Novo Nordisk scores major legal win that bars many compounded versions of Wegovy, Ozempic
Novo Nordisk scored a huge legal victory that largely restricts compounding pharmacies from marketing or selling cheaper, unapproved versions of the drugmaker's blockbuster weight loss drug Wegovy and diabetes treatment Ozempic.
A federal judge in Texas late Thursday rejected a bid by compounding pharmacies to keep making copies of Ozempic and Wegovy while a legal challenge over the shortage of those drugs unfolds. That came in response to a February lawsuit from a compounding trade group against the Food and Drug Administration's determination that the active ingredient in those drugs, semaglutide, is no longer in shorter in the U.S.
Patients flocked to the cheaper copycats when Ozempic and Wegovy were in short supply over the last two years due to skyrocketing demand, or if they didn't have insurance coverage for the costly treatments.
During FDA-declared shortages, pharmacists can legally make compounded versions of brand-name medications. Many telehealth companies, such as Hims & Hers, also offered those copycats. But drugmakers and some health experts have pushed back against the practice because the FDA does not approve compounded drugs, which are essentially custom-made copies prescribed by a doctor to meet a specific patient's needs.
"We are pleased the court has rejected the compounders' attempts to undermine FDA's data-based decision that the shortage" of semaglutide is resolved, said Steve Benz, Novo Nordisk's corporate vice president, legal and U.S. general counsel, in a statement.
"Patient safety remains a top priority for Novo Nordisk and the extensive nationwide legal actions we have taken to protect Americans from the health risks posed by illegitimate 'semaglutide' drugs are working," he said, referring to the company's more than 100 lawsuits against compounding pharmacies and other entities across 32 states.
On Thursday, U.S. District Judge Mark Pittman specifically denied the Outsourcing Facilities Association's bid for a preliminary injunction that would have prevented the FDA from taking action against its members for making copies of semaglutide.
That decision upholds the FDA's previous determination that the semaglutide shortage in the U.S. is over and means the FDA can now immediately go after so-called 503A pharmacies that are making compounded versions of semaglutide according to individual prescriptions for a specific patient.
Those pharmacies are largely regulated by states rather than the FDA.
Those pharmacies make compounded drugs according to individual prescriptions for a specific patient and are largely regulated by states rather than the FDA.
The decision also means the FDA can start targeting federally regulated 503B pharmacies, which manufacture compounded drugs in bulk with or without prescriptions, after May 22. The agency's actions can include product seizures and warning letters to pharmacies.
The decision on Thursday follows another win for Novo Nordisk. A different federal judge in Texas earlier this week ruled in favor of the drugmaker against a 503A pharmacy, MediOak Pharmacy, permanently prohibiting the business from marketing or selling compounded semaglutide.
Novo Nordisk and Eli Lilly have aggressively cracked down on compounding pharmacies over the last two years as they benefit from the soaring popularity of their weight loss and diabetes drugs.
Eli Lilly has gone through a similar legal process with tirzepatide, the active ingredient in its weight loss drug Zepbound and diabetes treatment Mounjaro. The FDA declared the U.S. shortage of tirzepatide over last year, prompting the same compounding trade group to sue the FDA over the drug.
In March, a federal judge denied the compounding group's request for a preliminary injunction on the FDA's enforcement against its members for making copies of Mounjaro and Zepbound. The compounding group has appealed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Bloomberg
44 minutes ago
- Bloomberg
Why Is Huawei Downplaying Its Chips?
It may seem like odd messaging from a tech chief. But Huawei Technologies Co. founder Ren Zhengfei said that Americans have 'exaggerated' his company's chip achievements, which 'still lag behind the US by a generation.' When it comes to the race for the hardware needed to support artificial intelligence, his company 'isn't that powerful yet,' Ren added in a lengthy front-page interview with the People's Daily this week. Still, there is 'no need to worry' about the US restrictions, he insisted. By bundling Huawei's chips together, or so-called clustering, they can still match rival offerings from top global players.
CNBC
an hour ago
- CNBC
The U.S. dollar hasn't been this weak in 3 years. What that means for stock investors
The U.S. dollar index on Thursday hit its lowest level since late March 2022 — putting renewed spotlight on what has been one of the biggest stories in financial markets this year: the weakening greenback. As the world's reserve currency, the U.S. dollar is held in large quantities by global central banks. Key commodities such as gold and oil are priced in dollars. Many foreign transactions, even when American parties aren't involved, also are conducted in dollars. When something that important reaches multiyear lows, investors and consumers alike are forced to consider the implications of the move for U.S. markets and the economy as a whole. At the heart of it is exchange rates. What is the rate at which a foreign buyer can exchange their local currency for dollars? And what is the rate at which Americans can exchange their dollars for foreign currencies? Those who have traveled internationally are likely quite familiar with this. From the investor perspective, the question is how the strength of the dollar plays into our companies' sales and earnings. The U.S. dollar index, which measures the greenback against a basket of foreign currencies including the euro and Japanese yen, has trended lower since January. However, its losses picked up steam after President Donald Trump announced his "Liberation Day" tariffs on April 2. While many assets sold off then and have since recovered, the dollar hasn't shared the same fate. When the dollar is strong, foreign buyers need to trade in more of their local currency — the currency they save and spend in — for U.S. dollars in order to purchase any dollar-denominated goods. Keep in mind: Even if a European purchases an iPhone in euros, those euros are eventually converted to dollars and that conversion rate is going to factor into the euro-denominated price that European shoppers may see in their local store. On the other hand, a weak dollar means that foreign buyers have relatively more buying power. When their local currency strengthens against the dollar, they can trade in fewer local currency units such as euros for an equal number of dollars. In effect, the price has gone down, a dynamic that usually leads to an increase in demand — all else equal. Sales going up because the foreign buyer feels a relative increase in their buying power is one reason why a weaker dollar is generally positive for U.S. companies' overseas business. To be sure, in this scenario, the U.S. company may see an increase in costs for any supplies that it needs to import from foreign countries because their dollars are worth less. However, because companies sell goods and services for more than it costs to make them, the end result is generally a net positive for earnings — the magnitude of that benefit depends, of course, on the share of sales generated outside the U.S. and the makeup of the supply chain. On Microsoft's most recent earnings call, CFO Amy Hood illustrated this dynamic (FX is shorthand for foreign exchange): "With the weakening of the U.S. dollar in April, we now expect FX to increase total revenue growth by 1 point. Within the segments, we expect FX to increase revenue growth by 1 point in Productivity and Business Processes and less than 1 point in Intelligent Cloud and More Personal Computing. We expect FX to increase [cost of goods sold] operating expense growth by less than 1 point." As we see, Microsoft is expecting cost of goods sold to increase at a lower percentage than the benefit to revenue growth. Indeed, we heard similar commentary Thursday from Wall Street veteran and IBM Vice Chair Gary Cohn. Appearing on CNBC's "Squawk Box" on Thursday morning, Cohn affirmed that the weaker dollar is good for IBM. "Yeah, it is," he said. "IBM is an American-based manufacturing company that sells a lot of overseas and repatriates earnings. Think of U.S. domiciled multinational corporations that sell product overseas and report dollar-based earnings." To recap: For investors, a weaker dollar should generally be viewed as a tailwind for foreign sales of U.S. companies — even though some of the benefit may be offset by inputs sourced from foreign markets that are purchased in dollars. The net effect on the bottom line depends on each individual companies' mix of foreign and domestic sales and inputs. There are additional ripple effects on consumer behavior that investors should monitor, beyond the euro-denominated iPhone example we touched on above. Arguably the most important is travel demand, which obviously impacts all sorts of companies including Club name Disney and Bullpen member Airbnb . A weaker dollar means that U.S. citizens traveling abroad will need to convert more dollars than before into the currency of their destination. Consequently, U.S. consumer appetite for international travel should be expected to take a bit of a hit. Back in 2022, when the euro and dollar hit parity for the first time in two decades , everyone was talking about how good it was to be an American traveler going to Europe that summer. It's a different ballgame now. The beneficiaries this summer are foreign travelers coming to the U.S., who will arrive with relatively more buying power than they otherwise would have in January. The U.S. dollar index ended that month around 108. It's around 98 on Thursday. The implication is that a trip to Disney's theme parks in Florida and California is relatively more affordable for intentional travelers than it was just a few months ago. In this way, U.S. companies also may be able to benefit in the domestic market from an increase in foreign tourism — unless there are other countervailing forces that would make them want to travel elsewhere . How does all of this play into our investment decisions? The answer is that it's one data point that we consider in the much larger universe of data. As fundamental investors, we must be aware of the implications of macroeconomic forces such as currency markets. But they do not, by themselves, drive our moves. Consider the case of Apple , where its growth potential in foreign markets is a major opportunity and reason to be optimistic about its future. In that sense, it's reasonable to assume that a weaker dollar would be a positive for the company – and indeed, it is. However, it is not a large enough positive for us to forget about all the other headwinds for Apple. Sure, the dollar is weaker, but it still must deal with tariffs resulting from where its goods are manufactured. There are court battles threatening its lucrative services business. Of course, there's the seeming lack of progress on Apple Intelligence. History suggests Apple is a strong enough operator to navigate these issues – and we are not counting them out of the AI race just yet, given its record-high installed base is a major advantage. The point is that there are much bigger considerations in our investment decisions than currency fluctuations. Or consider the case of Home Depot , which does 92% of sales in the U.S. but sources many goods internationally. The dollar is headwind – to the tune of $275 million in sales in the first quarter – given that the bulk of demand comes from U.S. consumers and the weak dollar serves to increase the supply costs (not unlike an import tariff). However, that is not in our view enough to sell the stock, not when interest rates are expected to decline and in turn provide a boost to the housing market, whether that's through renovations or new building activity. Finally, while we won't get too political, investors should also keep tabs on what is fueling the move in currency markets. In a lot of cases, the "why" behind the move is likely to be far more useful to investors than the absolute strength or weakness of the greenback. In other words, we must ask ourselves what is causing the move, and then ask ourselves what that cause means for our investments. For example, consider a situation where the dollar is weakening simply because interest rates are expected to move lower as the rate of inflation declines – and so there's less demand for U.S. government bonds and the dollars needed to purchase those bonds. That's a pretty solid reason for a weakening dollar and there wouldn't be a cause for concern among investors. On the other hand, if the dollar – or any other currency for that matter – is weakening because investors are growing concerned about the stability in that country, that would likely be cause for concern because it may portend a fundamental shift in capital flow dynamics. In the end though, these are more so concerns for macro-oriented investors. As primarily bottoms-up fundamental investors with a long-term time horizon, we are much more focused on happening with companies themselves — and the industries they're operating in — than we are with the strength of the U.S. dollar in any given stretch of time. (Jim Cramer's Charitable Trust is long HD, DIS and AAPL. See here for a full list of the stocks.) As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust's portfolio. If Jim has talked about a stock on CNBC TV, he waits 72 hours after issuing the trade alert before executing the trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB. NO SPECIFIC OUTCOME OR PROFIT IS GUARANTEED.
Atlantic
an hour ago
- Atlantic
The Best Wellness Advice Has Always Been Free
This is an edition of Time-Travel Thursdays, a journey through The Atlantic 's archives to contextualize the present. Sign up here. Allow me to make myself sound very dainty and attractive: Last year, I was diagnosed with inflammatory bowel disease. This was an unfortunate development, I decided, and so not in line with ' brat summer.' I handled the news like any journalist might—with compulsive research and fact-checking. My fear directed me to Reddit threads and scientific studies, to new diet plans and workout regimens and supplement orders, until my unremitting quest for answers landed me in the Zoom office of a functional-medicine doctor, a woman who charged me a couple of hundred bucks to tell me that I should eat more boiled plantains. My search for wellness had gone too far. I was spending money I didn't have to try to fix an illness with origins I'd never understand, much less control. Yet I trust that I'm far from alone in this desire to feel good. Every year, the average American spends more than $6,000 on 'wellness,' an imprecise category that includes both fads and legitimate endeavors, with offerings as varied as diagnostic technologies and protein popcorn. Across the world, wellness is a $6.3 trillion business—outpacing even the pharmaceutical industry—and Americans are by far the biggest spenders. Although some health issues require interventions or specialists (which can be exorbitantly expensive), the wellness industry tells Americans that no matter their condition—or lack thereof—there's always some treatment they should be buying. There's always more Googling and optimizing to be done. Take the journalist Amy Larocca's book, How to Be Well, which details her wellness-industry misadventures, including 'gravity' colonic cleanses, $200-a-month prescription herbs, and $1,000 Goop events. In a recent Atlantic review of the book, the writer Sheila McClear observed how widespread the 'wellness craze' has become, noting that 'in a nation known for its relatively poor health, nearly everybody seems to be thinking about how to be healthy.' Yet, like the human body's frailty, America's obsession with wellness is far from new. In our archives, I found a letter addressed to someone else facing an unsexy stomach ailment: ' A Letter to a Dyspeptic,' published in 1859, includes some remarkably sassy advice from an anonymous writer to a 19th-century gentleman with indigestion. This writer is all tough love, unafraid to call the gentleman an 'unfortunate individual,' a man of 'ripe old age, possibly a little over-ripe, at thirty-five,' and, due to the fellow's unique bathing habits, an 'insane merman.' The dyspeptic man had spent the past years suffering, quitting his business and doling out cash to questionable doctors and therapies, to little avail. 'You are haunting water-cures, experimenting on life-pills, holding private conferences with medical electricians, and thinking of a trip to the Bermudas,' the author writes. But this search for a cure came at a high cost: 'O mistaken economist! can you afford the cessation of labor and the ceaseless drugging and douching of your last few years?' Any hyperfixation on wellness can be draining and futile; an endless search for answers to one's ailments might be alluring, but 'to seek health as you are now seeking it, regarding every new physician as if he were Pandora,' the writer warns, 'is really rather unpromising.' In lieu of expensive treatments, the writer advises that the dyspeptic man do three things: bathe, breathe, and exercise. (Another suggestion is to purchase 'a year's subscription to the 'Atlantic Monthly,'' one of the 'necessaries of life' for happiness—it seems we writers have never been above the shameless plug.) Notably, all of these (except the Atlantic subscription, starting at $79.99) are more or less free. Written almost two centuries later, Larocca's book ends on a similar note, championing the kind of health advice that doesn't hurt your wallet. After her tiresome and expensive foray into the world of wellness, she 'doesn't recommend a single product, practice, or service, although she does name one tip that helped her,' McClear notes. 'It's a simple breathing exercise. And it's free.' America's wellness methods have changed over time—sometimes evolving for the better. (The 1859 letter, for instance, details how some philosophers believed in being as sedentary as possible because 'trees lived longer than men because they never stirred from their places.') Even so, as skyrocketing costs and medical mistrust plague American health care, the wellness industry churns out a carousel of treatments, touting sweeping benefits that are often dubious at best. Compared with the many big promises that 'gravity' colonics and supplement companies might make, most health tips that have stood the test of time are far more quotidian: sleep, exercise, breathe. Their simplicity can be both healing and accessible. The body has 'power and beauty,' the anonymous writer noted more than a century ago, 'when we consent to give it a fair chance.'
